Clinical Trial Update: Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating radiotherapy in combination with QL1706 and bevacizumab for unresectable non-metastatic hepatocellular carcinoma; the study status…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• QL1706

Snippet

Sponsor: Hebei Medical University Fourth Hospital | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING